FibroGen Reports Second Quarter 2023 Financial Results Topline data from three late-stage pamrevlumab trials expected through 1H 2024, including the Pancreatic Cancer Action Network (PanCAN) Precision PromiseSM Phase 2/3 study in metastatic pancreatic...

FibroGen to Report Fourth Quarter and Full Year 2022 Financial Results SAN FRANCISCO, Feb. 17, 2023 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) will announce its fourth quarter and full year 2022 financial results on Monday, February 27 after the market close....

FibroGen to Participate at Bank of America 2022 Biotech SMID Cap Virtual Conference SAN FRANCISCO, Nov. 28, 2022 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that Enrique Conterno, Chief Executive Officer, will participate in a fireside chat at the Bank of...

GTDC Launches Global Anti-Bribery and Anti-Corruption Platform ST. PETERSBURG, FL--(Marketwired - Apr 7, 2014) - The Global Technology Distribution Council (GTDC) today announced that it has launched an anti-bribery and anti-corruption (ABAC) due diligence...